Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-14 00:00:00 ET · period of report 2023-02-10 · accession 0001209191-23-009232 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-14 | 2023-02-10+ | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $297.58 | -5,242 | 62.0K | -8% | -$1.56M |
| 2023-02-14 | 2023-02-13 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.39 | -113 | 61.9K | -0.2% | -$33.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-10 | F | D | 902 | $294.33 | 66,368 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-13 | F | D | 4,340 | $298.26 | 62,028 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-13 | S | D | 113 | $300.39 | 61,915 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79). (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |